Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | An insight into CTX130: a novel allogeneic CAR-T cell therapy

Swaminathan Iyer • 10 Jun 2022
EHA 2022
General CAR-T CTX130

In this video, Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, briefly explains the CRISPR-CAS9 gene editing process behind CTX130 and how this gene editing process aims to improve the efficacy of this novel CAR-T agent. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE

More from Swaminathan Iyer

3:17
PET imaging to predict treatment outcomes: follow-up from the ECHELON-2 trial
Swaminathan Iyer • 11 Dec 2023
2:39
The significance of CD30 in the response to brentuximab vedotin for patients with T-cell lymphoma
Swaminathan Iyer • 11 Dec 2023
5:32
A machine learning model to analyze histopathological tissue in DLBCL
Swaminathan Iyer • 11 Dec 2023
2:57
Lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of R/R PTCL
Swaminathan Iyer • 11 Dec 2023

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals